Ascendis Pharma A/S (NASDAQ:ASND) Earns Overweight Rating from Cantor Fitzgerald

Ascendis Pharma A/S (NASDAQ:ASND)‘s stock had its “overweight” rating reiterated by equities researchers at Cantor Fitzgerald in a research note issued to investors on Monday,Benzinga reports. They currently have a $200.00 target price on the biotechnology company’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 23.82% from the stock’s current price.

Several other analysts have also recently commented on ASND. Wedbush raised their target price on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the stock an “outperform” rating in a research note on Friday, May 2nd. The Goldman Sachs Group raised their target price on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. raised their price objective on shares of Ascendis Pharma A/S from $200.00 to $245.00 and gave the company an “overweight” rating in a research note on Friday, May 2nd. Morgan Stanley upgraded shares of Ascendis Pharma A/S from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $180.00 to $250.00 in a report on Monday, May 5th. Finally, Royal Bank of Canada raised their target price on shares of Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an “outperform” rating in a report on Friday, May 2nd. One analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $216.07.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ:ASND opened at $161.52 on Monday. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $183.00. The stock has a market cap of $9.85 billion, a P/E ratio of -22.75 and a beta of 0.41. The firm has a fifty day moving average price of $156.29 and a 200 day moving average price of $141.85.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The firm had revenue of $123.97 million for the quarter, compared to the consensus estimate of $98.56 million. Sell-side analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ASND. T. Rowe Price Investment Management Inc. increased its stake in shares of Ascendis Pharma A/S by 54.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,725,546 shares of the biotechnology company’s stock worth $375,226,000 after buying an additional 960,504 shares during the last quarter. Capital International Investors increased its stake in shares of Ascendis Pharma A/S by 35.7% in the fourth quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company’s stock worth $394,183,000 after buying an additional 753,859 shares during the last quarter. RA Capital Management L.P. increased its stake in shares of Ascendis Pharma A/S by 4.1% in the fourth quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company’s stock worth $1,392,221,000 after buying an additional 402,316 shares during the last quarter. Vestal Point Capital LP increased its stake in shares of Ascendis Pharma A/S by 108.0% in the fourth quarter. Vestal Point Capital LP now owns 520,000 shares of the biotechnology company’s stock worth $71,588,000 after buying an additional 270,000 shares during the last quarter. Finally, Janus Henderson Group PLC increased its stake in shares of Ascendis Pharma A/S by 4.6% in the fourth quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company’s stock worth $602,910,000 after buying an additional 193,688 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.